Economic Evaluations of Immunoprophylaxis in Infants at High Risk for Respiratory Syncytial Virus: Shedding Light or Creating Confusion?

GREAT ADVANCES in pediatrics have arisen from the discovery of new drugs designed to treat diseases that may cause death or severe morbidity in children. These discoveries most often arise from basic research and are brought to market by pharmaceutical companies at an estimated cost of $500 million per drug.¹ No one can dispute that much benefit to patients has emerged from these developments.